



FOR IMMEDIATE RELEASE

CONTACT:

Kuno van der Post Ph.D
Senior Vice President of Business Development,
OmniComm Systems, Inc.
954-473-1254
kvanderpost@omnicomm.com

Leading Biotechnology Company Renews Multi-Million Dollar Enterprise Agreement for *OmniComm Systems' TrialMaster EDC Solution*

Fort Lauderdale, FL, February 4th, 2013 – OmniComm Systems, Inc. (OTC: OMCM), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced the renewal of an Enterprise Agreement to deploy TrialMaster®, their Electronic Data Capture (EDC) suite, with one of the largest biotechnology companies in the U.S. This two year agreement is expected to generate over \$2M in revenue during the support of multiple clinical trial programs.

“We are honored that this leading biotech client has again chosen to partner with OmniComm for their clinical research needs,” commented Stephen Johnson, OmniComm’s President & COO. “This is a strong testament to the quality of the products and services that OmniComm delivers, and we look forward to continuing this fruitful partnership.”

This contract renewal is the latest in a string of new and recurring business with biotech clients. OmniComm attributes its success to many new innovative functions and features across its multiple product lines, and to its strong customer service and support programs.

“Biotechnology companies are at the forefront of medical research, and often need very sophisticated features to implement their study designs”, commented Keith Howells, OmniComm’s Senior Vice President of Development. “TrialMaster includes features such as guided data entry, risk-based monitoring and out-of-the-box generation of submission-ready datasets, which are very attractive to this industry. We are proud of this latest endorsement of our innovation strategy”.

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.



Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.